Search Results
Your search for ,NOt matches 22378 pages
Showing 20101 - 20150Anemia Prevalent and Independently Associated With Functional Disability in Older Patients With Cancer
“Anemia was highly prevalent and independently associated with functional disability” among older adults with cancer, according to an analysis of data conducted by Cynthia Owusu, MD, MS, of Case Western Reserve University, Cleveland, and colleagues. “Older patients with anemia were more than twice...
Increased Risk of Second Nonmelanoma Skin Cancer Among Patients Receiving Immunosuppressive Therapy
Patients with rheumatoid arthritis treated with methotrexate had an increased risk of a second nonmelanoma skin cancer, and adding anti–tumor necrosis factor (TNF) may increase that risk, according to results of a retrospective cohort study reported in JAMA Dermatology. A similar association was...
The Sixth Edition of the Essential Breast Cancer Book
Bookmark Title: Dr. Susan Love’s Breast Book Author: Susan M. Love, MD Publisher: Da Capo Lifelong Books Publication date: September 8, 2015 Price: $24.00; paperback, 704 pages For more than 25 years, Dr. Susan Love’s Breast Book has been the best source of information for women with breast...
Integrating Spirituality Into Palliative Care Services
Over the past couple of decades, the oncology community has made great strides in mediating the psychosocial needs of our patients. However, a patient’s spirituality is a subjective and uncomfortable issue for many oncologists, which leaves a gap in the continuum of care. To reach a better...
Expert Point of View: Ricky A. Sharma, MA, MB, BChir, PhD
Ricky A. Sharma, MA, MB, BChir, PhD, of Gray Institute for Radiation Oncology and Biology at the University of Oxford, United Kingdom, formally discussed the paper. He disclosed that he is a co-principal investigator for the FOXFIRE study, which is currently evaluating selective internal radiation...
Chemoradiotherapy for Liver Metastases
The phase III SIRFLOX trial showed that selective internal radiation therapy delivered to liver metastases in patients with colorectal cancer, plus chemotherapy, improved local control, although median progression-free survival for the whole population was not affected. Median progression-free...
Selective Internal Radiation Therapy Impacts Liver Metastases in Colorectal Cancer
A novel interventional approach to treating liver metastases associated with colorectal cancer improved control of liver metastases, according to the SIRFLOX study presented at the 2015 ASCO Annual Meeting.1 The addition of selective internal radiation therapy to first-line chemotherapy extended...
Expert Point of View: Martine Piccart, MD, PhD
Martine Piccart, MD, PhD, Professor of Oncology at the Université Libre de Bruxelles, Belgium, and President of the European Cancer Organisation, said she found it “distressing” to see such large variations in 5-year survival across European countries. “I would like to stress the fact that these...
You’ve Lived A Good Life
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Yet Another Reason Why Dogs Are Our Best Friends
BookmarkTitle: Heal: The Vital Role of Dogs in the Search for Cancer CuresAuthor: Arlene WeintraubPublisher: ECW PressPublication date: October 13, 2015Price: $16.95; paperback, 240 pages Comparative oncology, a fairly recent addition to the ever-evolving world of cancer research, studies the...
Racial Issues on the Road to Medicine
BookmarkTitle: Black Man in a White Coat: A Doctor’s Reflections on Race and MedicineAuthor: Damon Tweedy, MDPublisher: Picador, Macmillan PublishingPublication date: September 8, 2015Price: $26.00; hardcover, 304 pages Strained race relations over issues whose foundation is based on inequality...
The Highs and Lows of a Transplant Surgeon
Bookmark Title: Last Night in the OR: A Transplant Surgeon’s OdysseyAuthor: Bud Shaw, MDPublisher: Plume, division of Penguin GroupPublication date: September 15, 2015Price: $16.00; paperback, 304 pages Surgery has a distinct place in medicine. Surgeons cut deep into our bodies amid clusters of...
Ixazomib in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 20, 2015, ixazomib (Ninlaro) was approved by the U.S....
Daratumumab in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 16, 2015, daratumumab injection (Darzalex) was...
Parotid Tumor Excision, Albumen Print, Paris, February 1872
A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The Anesthesia Era 1845-1875.” To view additional...
Osimertinib for Metastatic EGFR T790M–Mutant Non–Small Cell Lung Cancer After EGFR Inhibitor Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 13, 2015, osimertinib (Tagrisso) was granted...
Lung Cancer: Hope From Science
The following essay by Paul A. Bunn, Jr, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I grew up...
A Swiss Psychotherapist Gives Her Perspective on Optimal Palliative Care
Over the past few decades, the oncology community has incorporated new evidence-based therapies to address the psychosocial needs of patients with cancer, especially those with advanced disease. To bring a global perspective to this evolving discipline, The ASCO Post recently spoke with Monika...
A Blueprint for Drug/Diagnostic Development: Expansion and Use of Curated Genetic Databases
In a continuation of a 2014 conference that explored regulatory considerations and strategies for next-generation sequencing, the Friends of Cancer Research, with support from Alexandria Real Estate Equities, Inc, Pasadena, California, met to discuss the issues and problems of coordinating drug and ...
Foot Care in Oncology: The Cancer Patient From Ankle to Toe
There is as yet no clinical or research focus on foot complications that result from cancer therapies. Foot conditions, however, are common and have a considerable negative impact on patients’ ambulation, quality of life, and consistent dosing of antineoplastic agents.1-4 There are currently no...
Practicing the Humanistic and Holistic Approach to End-of-Life Care
In 1990, when Bruce (B.J.) Miller, MD, was an undergraduate at Princeton University, the practice of medicine was far from his mind. Then a student in Chinese and Asian studies and later an art history major, Dr. Miller would come to pursue a career specializing in palliative medicine after an...
The Complex Interactions of Treatment Costs, Clinical Outcomes, and Patient Expectations
A clinical dilemma that is receiving a great deal of attention in the oncology community is the undue financial burden some patients face during their treatment and into survivorship. While much emphasis is put on methods to reduce and help patients navigate the complex payment system, little is...
Cancer Care in Low-Resource Areas: Some Improvements Over the Years, but Serious Problems Remain
Low- and middle-income countries bear a larger share of the global cancer burden than does the developed world,” said Greta Massetti, PhD, Associate Director for Science, Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control and Co-Chair of the National Cancer...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Argentina
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Argentina. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For ...
Gut Bacteria May Facilitate Efficacy of Anti–PD-L1 Agents
Could the manipulation of bacteria in the gut pack the same punch in melanoma as antibodies targeting the programmed cell death protein and its ligand (PD-1/PD-L1)? It’s possible, at least in mice, according to research from the University of Chicago, recently published in Science.1 The researchers ...
This December: Triple Your Impact
Earlier this year, Conquer Cancer Foundation (CCF) Board Member Raj Mantena, RPh, announced his intention to match individual donations to CCF dollar-for-dollar, up to $1 million, throughout the month of September. His generous support of The Campaign to Conquer Cancer—a comprehensive, $150 million ...
Making a Difference for Patients: An Interview With Dr. Daniel F. Hayes, 2015–2016 President-Elect
Daniel F. Hayes, MD, FASCO, began his term as ASCO President-Elect this past June, and will serve as President in 2016–2017. A breast cancer specialist, he is Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at ...
Nodal Irradiation in Node-Positive Breast Cancer: It Is Not Time to Change Practice
Management of the regional nodes in breast cancer has evolved from the era of the extended radical mastectomy to exclusion of axillary dissection in appropriately selected patients. Throughout this evolution, studies of nodal irradiation have been shown to improve locoregional control, usually...
Regional Nodal Irradiation in Early Breast Cancer Yields Significant Disease-Free Survival Benefit in Two Trials
Two phase III trials recently reported in The New England Journal of Medicine indicated that the addition of regional nodal irradiation was associated with no or marginal overall survival benefit but significantly improved disease-free survival in patients with early-stage breast cancer.1,2 NCIC...
ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Systemic Therapy for Women With Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Catherine Van Poznak, MD, and colleagues, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer.1 The statement is based on an ASCO expert panel review...
Nivolumab Improves Overall Survival vs Docetaxel in Advanced Previously Treated Squamous Cell NSCLC
In a phase III trial reported in The New England Journal of Medicine, Julie Brahmer, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, and colleagues found that treatment with the programmed cell death protein 1 (PD-1) immune checkpoint inhibitor antibody nivolumab...
Evidence-Based Practice Needed in End-of-Life Care
Evidence-based oncology practice is a systematic approach to problem solving for cancer care providers, characterized by the use of the best evidence currently available for clinical decision-making. Over the past several decades, the oncology community, led by its major organizations such as ASCO...
Understanding Health-Care Disparities Among Lesbian, Gay, Bisexual, and Transgender Patients to Ensure More Effective Cancer Care
A new study examining the health-care needs of lesbian, gay, bisexual, and transgender/transsexual patients has found myriad disparities in access to cancer care.1 The researchers reviewed nearly 170 papers published over the past 15 years on the health-care needs among this population. Although...
Closing the Racial Survival Disparity Gap in Breast Cancer: Models for Change From Chicago, New York, and Beyond
It has long been said that white women of European ancestry are more likely to be diagnosed with breast cancer, but African American women are more likely to die of it. This statement has introduced multiple articles on the topic of the racial survival disparity in breast cancer, including our own...
Reducing Racial Disparities in Breast Cancer Incidence and Mortality Trends to Improve Outcomes
A recent report by DeSantis and colleagues from the American Cancer Society, summarized in this issue of The ASCO Post, presented breast cancer incidence and mortality data from an extensive analysis of the U.S. system of state-based tumor registries.1 The data showed that the incidence of breast...
Convergence of Breast Cancer Incidence but Continued Divergence of Mortality in Black Women and White Women
In an article published in CA: A Cancer Journal for Clinicians, Carol E. DeSantis, MPH, and colleagues from the American Cancer Society reported that the incidence of breast cancer in black women has caught up to that in white women, whereas the risk of mortality continues to be higher in black...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The FDA approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC. Necitumumab is a recombinant human IgG1...
Cobimetinib in BRAF-Mutant Unresectable or Metastatic Melanoma in Combination With Vemurafenib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs On November 10, 2015, the U.S. Food and Drug Administration...
Trabectedin in Liposarcoma/Leiomyosarcoma: The Drug Is Approved, Now the Real Drug Development Begins!
Led by George Demetri, MD, of Dana-Farber Cancer Institute, Boston, expert medical oncology investigators from leading academic sarcoma centers and Janssen Pharmaceuticals employees performed a phase III trial in order to provide evidence for the U.S. Food and Drug Administration (FDA) approval of...
Molecularly Targeted Therapy Brings New Hope to Patients With Relapsed/Refractory Hairy Cell Leukemia
The treatment of hairy cell leukemia is one of the great success stories in hematologic malignancies, with patients now having a survival that is only slightly inferior to an age-matched normal population. Purine analogs, such as cladribine, are the mainstay of first-line therapy, with...
Nivolumab Receives Two FDA Approvals in November
Nivolumab (Opdivo) is a monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with its ligands PD-L1 and PD-L2, releasing PD-1 pathway–mediated inhibition of the immune response. Late last month, the U.S. Food and Drug Administration (FDA)...
BRAF Inhibition Successful in Relapsed/Refractory Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Enrico Tiacci, MD, of the University of Perugia, Italy, and colleagues found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia that relapsed...
Clinical Trial Design in Older Patients
Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology. Increasing age is directly associated with an increasing risk of cancer,...
Mind-Body Therapies Were the Focus at the 12th International Conference of the Society for Integrative Oncology
Among the highlights at the 12th International Conference of the Society for Integrative Oncology (SIO) was a 1-day joint meeting on acupuncture, oncology, and fascia cosponsored by SIO, the Society for Acupuncture Research, the Fascia Research Society, and the Osher Center for Integrative...
FDA Approves Elotuzumab in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted approval for elotuzumab (Empliciti) in combination with two other therapies to treat patients with multiple myeloma who have received one to three prior medications. “We are continuing to learn about the ways the immune system interacts with...
2015 Review of Newly Approved Oncologic Therapies
Over the past year or so, a host of new agents were approved for the treatment of patients with various types of cancer (see related article on page 1). Patrick Medina, PharmD, of the University of Oklahoma College of Pharmacy, Oklahoma City, and Monique Giordana, PharmD, BCOP, of Regions...
Ovarian Cancer: Current Treatment and Patient Management
Tough initial treatment decisions have “long-lasting ramifications and affect the entire treatment paradigm” for women with ovarian cancer, according to Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona Cancer Center, Phoenix. In a true collaborative presentation at the Annual JADPRO...
Expert Point of View: Charles E. Geyer, Jr, MD, FACP
Discussant Charles E. Geyer, Jr, MD, FACP, Associate Director for Clinical Research at Virginia Commonwealth University Massey Cancer Center in Richmond, Virginia, singled out the power of this study’s dataset. “In 2002,” he said, “the Institute of Medicine named NSQIP [National Surgical Quality...
Neoadjuvant Chemotherapy Appears to Have No Effect on Short-Term Outcomes in Breast Cancer Surgery
Patients who received neoadjuvant chemotherapy within 30 days prior to breast cancer surgery did not appear to be at increased risk for overall postoperative complications, according to a study presented at the 2015 Breast Cancer Symposium.1 “Although on unadjusted analysis there were more...
Tumor Profiling of Breast Tumors in Older Patients Reveals Differences From Those of Younger Patients
Using multiplatform profiling, researchers have identified potentially targetable biomarker aberrations in a large cohort of geriatric breast tumors.1 According to the study, presented at the 2015 Breast Cancer Symposium, these data may help researchers to design clinical trials focusing on...
